HotSpot heads for clinic with $65M series B round to develop allosteric modulators
With strategics, one crossover on board, HotSpot is likely to raise mezzanine round before exploring IPO
Allostery company HotSpot has added strategic and crossover investors to the mix for a $65 million series B round designed to take two small molecules into the clinic, but the company believes it will still take a mezzanine round to clear the path for an IPO.
On Thursday, HotSpot Therapeutics Inc. said SR One led the series B
